Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Jabil Inc (JBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Jabil Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Jabil Inc trades at $289.3 (market cap $33.31B). The key difference: Jabil Inc is far larger — about 3.9× Hinge Health Inc. Class A Common Stock's market cap, and Jabil Inc pays a 0.1% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Jabil Inc for 24 Days on average.
| HNGE | JBL | |
|---|---|---|
Market Cap | $8.48B | $33.31B |
Volume | 879,799 | 1,264,382 |
Sector | Health | Technology |
52-Week High | $105.14 | $385.50 |
52-Week Low | $31.17 | $192.49 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $8.10B | $35.59B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
JBL trades at $317.86, up 1.87% with strong technical momentum and bullish moving averages. The company delivered three consecutive earnings beats, with Q2 2026 EPS of $4.40 beating expectations of $4.07. Revenue growth is accelerating, with fiscal 2027 guidance projecting 24% growth driven by AI infrastructure demand. Analyst consensus remains strongly bullish with a $434.75 price target representing 37% upside potential.
The outlook remains positive with AI-driven growth catalysts and strong institutional support, though risks include execution challenges in scaling operations and market volatility despite strong fundamentals. Current valuation at 32.6 P/E appears reasonable given the growth trajectory, while the 74.11% ROE demonstrates exceptional capital efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
